CMPX Capital raise

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Published August 13, 2025 at 02:28 AM

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to custom

Related Questions

How will the $3.00 per share pricing compare to Compass Therapeutics' recent trading range and affect immediate market reaction? What is the expected dilution impact from issuing 33,290,000 new shares and the 6,710,000 pre‑funded warrants on existing shareholders? How will the proceeds of approximately $120 million be allocated—e.g., toward clinical trials, R&D, or balance‑sheet strengthening—and what milestones are anticipated? What are the specific terms of the pre‑funded warrants (exercise price, expiration date, and any redemption or conversion features) and how might they influence future equity supply? What underwriting discounts, commissions, and offering expenses are anticipated, and how will they affect net proceeds versus gross proceeds? Is there a lock‑up period for existing insiders or early investors, and what is the expected timeline for secondary offerings or further capital raises? How does this upsized public offering size and pricing compare to Compass Therapeutics' previous capital raises and to recent offerings by peer oncology‑focused biotech companies? Will the increased float from this offering improve liquidity and reduce bid‑ask spreads for CMPX shares? What potential impact could the warrant over‑hang have on the stock price if the warrants are exercised in the near term? How might the market interpret the need for a $120 million raise—does it signal cash‑flow constraints, accelerated development plans, or strategic expansion?